Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
Chris Parker(Royal Marsden NHS Foundation Trust), Dominic Hague, Stephen Morris(King's College London), Raj Persad(North Bristol NHS Trust), Mahesh Parmar(University College London), Adrian Cook(University College London), Anjali Zarkar(Cancer Research UK), Peter Hoskin(University of Manchester), Shawn Malone, Jennifer Mary Rose Branagan(Northampton General Hospital), Katharine Bellenger, William Cross(Leeds Teaching Hospitals NHS Trust), Claire Amos(MRC Clinical Trials Unit at UCL), Christina Chung(University Health Network), Abdenour Nabid, Katherine E. Beaney, Andrew Embleton-Thirsk(University of Waterloo), Lyn Cogley(Derriford Hospital), Alison Tree(Royal Marsden NHS Foundation Trust), Ananya Choudhury(University of Manchester), Jenna Grabey, Chee Goh(Institute of Cancer Research), David Bottomley(San Antonio College), Cindy Goldstein(MRC Clinical Trials Unit at UCL), Fred Saad(Centre Hospitalier de l’Université de Montréal), Lindsey Masters(MRC Clinical Trials Unit at UCL), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Silvia Forcat(MRC Clinical Trials Unit at UCL), Wendy R. Parulekar(Unknown), Noel W. Clarke(The Christie NHS Foundation Trust), Jane Worlding(University Hospitals Coventry and Warwickshire NHS Trust), Rakesh Raman(Kent and Canterbury Hospital), Howard Kynaston(Cardiff University), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Maroie Barkati(Centre Hospitalier de l’Université de Montréal), Chris Brawley(Cancer Research UK), Peter Chung(Princess Margaret Cancer Centre), Heather Payne(The Prostate Centre), J R Anderson(St James's University Hospital), John Logue(San Antonio College), James Wylie(Cancer Research UK), A. Ong(University of Manitoba), Lorna C Bower(Royal Marsden NHS Foundation Trust), Charles Catton(University of Toronto), Kathryn Tarver(Queen's Hospital), Claire Murphy(University College London)
Cited by 50
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k